Molnupiravir is a prodrug of the synthetic nuceloside derivative N4-hydroxycytidine, currently tested in a Phase 2/3 trial against SARS-COV-2 that is set to be completed in May 2021.
Big question:
Molnupiravir is structurally similar to cytarabine, will it also have side effects similar to cytarabine?
Cytarabine:
References:
1. https://clinicaltrials.gov/ct2/show/NCT04405739
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
3. https://www.biorxiv.org/content/10.1101/2020.03.30.016485v1.full.pdf
Comments
Post a Comment